nrf2 inhibitor group  (MedChemExpress)

Journal: Frontiers in Cell and Developmental Biology

Article Title: Molecular insights into Atorvastatin’s role in delaying intervertebral disc degeneration

doi: 10.3389/fcell.2025.1693951

Figure Lengend Snippet: Ator promotes Nrf2 expression and its downstream gene activation. Nrf2 expression was detected by pretreatment with Ator for 6 h with the addition of 300 μM H 2 O 2 . (A) Immunofluorescence for Nrf2 expression. (B–G) Western blotting was performed to detect the expression of Total-Nrf2, HO-1, NQO-1, and Cytosolic-Nrf2 with β-actin as an internal reference and Nuclear-Nrf2 with Lamin-b as an internal reference. (H–J) Detection of Nrf2, NQO-1, and HO-1 expression using qPCR. All the data are shown as mean ± deviation, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: Ator, atorvastatin; ns, non-significant.

Article Snippet: NPC were divided into five groups: control group (routine culture without any treatment), H 2 O 2 group (induced using 300 um/mL H 2 O 2 ), Ator treatment group (10 umol/mL Ator (MCE, US) and 300 umol/mL H 2 O 2 co-treatment were selected), Nrf2 inhibitor group (10 μM Nrf2-IN-1 (MCE, US) plus 300 umol/mL H 2 O 2 co-treatment), Nrf2 inhibitor plus Ator group (10uM Nrf2-IN-1 plus 300 umol/mL H 2 O 2 and 10 umol/mL Ator co-treatment) Cells were incubated at 37 °C in a 5% CO 2 incubator for subsequent experiments.

Techniques: Expressing, Activation Assay, Immunofluorescence, Western Blot

Journal: Frontiers in Cell and Developmental Biology

Article Title: Molecular insights into Atorvastatin’s role in delaying intervertebral disc degeneration

doi: 10.3389/fcell.2025.1693951

Figure Lengend Snippet: Activation of Nrf2 is necessary for Ator to exert antioxidant effects. Addition of Nrf2-IN-1 treatment followed by Ator pretreatment for 6 h and H 2 O 2 treatment for 6 h (A–F) Western blotting for detection of relevant protein expression. Data are shown as mean ± deviation, n = 3. (G–I) qPCR for Nrf2, NQO-1, HO-1 expression. Data are shown as mean ± deviation, n = 3. (J) Antioxidant enzyme SOD expression. (K) ROS expression level. (L) CCK8 assay for cellular activity. Data are shown as mean ± deviation, n = 6. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: Ator, atorvastatin; Nrf2-IN-1, Nrf2 inhibitor; ns, non-significant.

Article Snippet: NPC were divided into five groups: control group (routine culture without any treatment), H 2 O 2 group (induced using 300 um/mL H 2 O 2 ), Ator treatment group (10 umol/mL Ator (MCE, US) and 300 umol/mL H 2 O 2 co-treatment were selected), Nrf2 inhibitor group (10 μM Nrf2-IN-1 (MCE, US) plus 300 umol/mL H 2 O 2 co-treatment), Nrf2 inhibitor plus Ator group (10uM Nrf2-IN-1 plus 300 umol/mL H 2 O 2 and 10 umol/mL Ator co-treatment) Cells were incubated at 37 °C in a 5% CO 2 incubator for subsequent experiments.

Techniques: Activation Assay, Western Blot, Expressing, CCK-8 Assay, Activity Assay

Journal: Frontiers in Cell and Developmental Biology

Article Title: Molecular insights into Atorvastatin’s role in delaying intervertebral disc degeneration

doi: 10.3389/fcell.2025.1693951

Figure Lengend Snippet: Schematic representation of Ator inhibition of H 2 O 2 -induced apoptosis in NPCs. Ator action on NPC causes Nrf2 to separate from Keap1 and enter the nucleus, which combines with ARE to promote the translation of downstream antioxidant proteins such as HO-1 and NQO-1 and inhibit H 2 O 2 -induced oxidative stress. It also reduced the activation of caspase-3 and inhibited apoptosis in NPC. Abbreviations:Nrf2, Nuclear factor erythroid 2-related factor 2; Keap1, Kelch-like ECH-associated protein 1; ROS, Reactive Oxygen Species; ARE, Antioxidant Response Element; HO-1, Heme Oxygenase-1; NQO-1, NAD(P) H Quinone Oxidoreductase 1; Bcl2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; H 2 O 2 , Hydrogen Peroxide.

Article Snippet: NPC were divided into five groups: control group (routine culture without any treatment), H 2 O 2 group (induced using 300 um/mL H 2 O 2 ), Ator treatment group (10 umol/mL Ator (MCE, US) and 300 umol/mL H 2 O 2 co-treatment were selected), Nrf2 inhibitor group (10 μM Nrf2-IN-1 (MCE, US) plus 300 umol/mL H 2 O 2 co-treatment), Nrf2 inhibitor plus Ator group (10uM Nrf2-IN-1 plus 300 umol/mL H 2 O 2 and 10 umol/mL Ator co-treatment) Cells were incubated at 37 °C in a 5% CO 2 incubator for subsequent experiments.

Techniques: Inhibition, Activation Assay

Journal: Journal of Ovarian Research

Article Title: Human mesenchymal stem cells derived exosomes improve ovarian function in chemotherapy-induced premature ovarian insufficiency mice by inhibiting ferroptosis through Nrf2/GPX4 pathway

doi: 10.1186/s13048-024-01403-6

Figure Lengend Snippet: hUMSC-exos alleviated CTX-induced ferroptosis in KGN cells. A Comparison of ROS levels in Nc group, POI group, POI + Exos group, and POI + Exos + ML385 group. B Detection of Fe2 + in Nc group, POI group, POI + Exos group, and POI + Exos + ML385 group by FeRhoNoxTM − 1 staining. C Statistical analysis results of ROS detection and FeRhoNoxTM − 1 staining. (** P < 0.01, *** P < 0.001, **** P < 0.001.)

Article Snippet: The cells were divided into four groups: the control group (Nc), the POI group (CTX, 1 mg/mL, POI), the hUMSC-derived exosomes (0.015 µg/µl) treatment group (POI + Exos), and the hUMSC-derived exosomes + NRF2 inhibitor treatment group (ML385, 1 µmol/L, MCE) (POI + Exos + ML385).

Techniques: Comparison, Staining

Journal: Journal of Ovarian Research

Article Title: Human mesenchymal stem cells derived exosomes improve ovarian function in chemotherapy-induced premature ovarian insufficiency mice by inhibiting ferroptosis through Nrf2/GPX4 pathway

doi: 10.1186/s13048-024-01403-6

Figure Lengend Snippet: hUMSC-exos alleviated CTX-induced lipid peroxidation in KGN cells. A Lipid peroxidation status in Nc group, POI group, POI + Exos group, and POI + Exos + ML385 group after 24 h of treatment. B Lipid peroxidation status in Nc group, POI group, POI + Exos group, and POI + Exos + ML385 group after 48 h of treatment. C Statistical results of Fig. 6A and B. (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.)

Article Snippet: The cells were divided into four groups: the control group (Nc), the POI group (CTX, 1 mg/mL, POI), the hUMSC-derived exosomes (0.015 µg/µl) treatment group (POI + Exos), and the hUMSC-derived exosomes + NRF2 inhibitor treatment group (ML385, 1 µmol/L, MCE) (POI + Exos + ML385).

Techniques: